Walker Luke Nathaniel
SEC insider (Form 3/4/5 filer). CIK 0001701440. Director at Context Therapeutics Inc. (CNTX) and 1 other issuer. 6 reported Form 4/5 transactions since Sep 2024; latest on Jun 24, 2026. Located in SAN DIEGO, CA.
Companies Walker Luke Nathaniel has filed insider reports for
- Context Therapeutics Inc. (CNTX): Director
- Zentalis Pharmaceuticals, Inc. (ZNTL): Director
Walker Luke Nathaniel
CIK: 0001701440
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 24, 2026CNTX
Context Therapeutics Inc.
AwardDirectStock Option (right to buy)
45K shares- - Jun 16, 2026ZNTL
Zentalis Pharmaceuticals, Inc.
AwardDirect57.1K shares- - Jun 17, 2025ZNTL
Zentalis Pharmaceuticals, Inc.
AwardDirect57.6K shares- - Jun 12, 2025CNTX
Context Therapeutics Inc.
AwardDirectStock Option (right to buy)
123.5K shares- - Jan 31, 2025ZNTL
Zentalis Pharmaceuticals, Inc.
PurchaseDirect14.2K shares at avg. $1.76$25K - Sep 4, 2024CNTX
Context Therapeutics Inc.
AwardDirectStock Option (right to buy)
19.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 24, 2026 |  CNTX Context Therapeutics Inc. | Award Stock Option (right to buy) | 45,000 | - | - | Direct |
| Jun 16, 2026 |  ZNTL Zentalis Pharmaceuticals, Inc. | Award | 57,100 | - | $0 | Direct |
| Jun 17, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | Award | 57,603 | - | - | Direct |
| Jun 12, 2025 | CNTX Context Therapeutics Inc. | Award Stock Option (right to buy) | 123,500 | - | - | Direct |
| Jan 31, 2025 | ZNTL Zentalis Pharmaceuticals, Inc. | Purchase | 14,200 | $1.76 | $24,966 | Direct |
| Sep 4, 2024 | CNTX Context Therapeutics Inc. | Award Stock Option (right to buy) | 19,315 | - | - | Direct |
1-6 of 6 transactions